All infants should receive the new long-acting preventive monoclonal antibody for respiratory syncytial virus (RSV), the nation’s leading pediatrics group said.
All infants should receive the new long-acting preventive monoclonal antibody for respiratory syncytial virus (RSV), the nation’s leading pediatrics group said.
Leave A Comment